AP NEWS

Onco360® Selected to Dispense XOSPATA® (Gilteritinib)

November 30, 2018

LOUISVILLE, Ky.--(BUSINESS WIRE)--Nov 30, 2018--Onco360 ®, the nation’s largest independent Oncology Pharmacy, announced today that it was selected as a specialty pharmacy network partner for Astellas’ new product XOSPATA ® (gilteritinib) for the treatment of patients with relapsed or refractory FMS-like Tyrosine Kinase 3 (FLT3) mutation-positive acute myeloid leukemia (AML).

“Onco360 is excited to be selected as one of only three specialty pharmacy providers for XOSPATA patients,” said Paul Jardina, President and CEO, Onco360. “The recent approval of XOSPATA unlocks a new treatment option for AML patients with extremely limited treatment alternatives. As a provider of this key treatment, Onco360 can support the highly specialized needs of AML patients and their physicians across the United States.”

AML is the most common form of acute leukemia in adults in the United States (U.S.). Only 27 percent of patients diagnosed with AML survive for five years following initial diagnosis. FLT3 mutations occur in about 33 percent of AML patients and is an indicator of a poor prognosis. The American Cancer Society estimates that in 2018, approximately 19,500 new patients will be diagnosed with AML in the U.S. 1 Previously, there were no U.S. Food and Drug Administration (FDA)-approved products for patients with relapsed or refractory FLT3 mutation-positive AML.

XOSPATA is a manufactured by Astellas Pharma Inc. and was approved by the U.S. FDA on November 28, 2018 based on positive clinical trial results. 2 Full prescribing information can be found at www.xospata.com.

XOSPATA is immediately available to order through Onco360. Referral forms and information on how to order can be found at Onco360.com/Order.

About Onco360®Oncology Pharmacy:

Onco360 is the largest independent Oncology Pharmacy and clinical support services company in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, ACHC-, and JCAHO-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com.

1 American Cancer Society, www.cancer.org. Key Statistics for Acute Myeloid Leukemia (2018). 2 Perl AE, et al. Lancet Oncol. 2017 Aug; 18(8): 1061-1075

View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005219/en/

CONTACT: PharMerica Corporation

Robert Dries, 502-627-7140

Executive Vice President and

Chief Financial Officer

KEYWORD: UNITED STATES NORTH AMERICA KENTUCKY

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL

SOURCE: Onco360

Copyright Business Wire 2018.

PUB: 11/30/2018 09:10 AM/DISC: 11/30/2018 09:10 AM

http://www.businesswire.com/news/home/20181130005219/en

AP RADIO
Update hourly